Wednesday, February 27, 2013

Thirteen AG-1478 ALK Inhibitor Myths Totally Exposed

Calcitonin was measured with Liaison calcitonin a Gen kit by the chemiluminescent immunoassay method. Data are expressed as means _ SD. Statistical significance for data was determined employing one way analysis of variance with post hoc test, and significance was calculated by LSD multiple range test to find inter group significance.

Among the tanshinone compounds, tanshinone IIA and cryptotanshinone had been selected as AG-1478 active and quality control compounds in this study. Calibration curves of the two compounds were constructed by measuring different concentrations. Good linearity was observed for tanshinone IIA and cryptotanshinone. The regression equations for tanshinone IIA and cryptotanshinone were y _ 59467x 296829 and y _ 62354x 109248, respectively. The typical HPLC UV profiles are illustrated in Additional file 1. The HPLC condition has been also described in Additional file 2. Good separation was achieved within 25 min. The retention times for cryptotanshinone and Tanshinone IIA were 14. 8 and 21. 6 min.
Other microstructural parameters such as SMI and trabecular bone pattern were also significantly different. SM treatment also showed some tendency for dose dependent safety effects but only the maximum ALK Inhibitor SM treatment of 30 mg/kg had a significant preventive effect, attenuating reduction of BV/TV by 24%, Tb. Th by 65%, Tb. N by 23% and Conn. D by 12%, while preventing increase of Tb. Sp by 43%, SMI by 30% and Tb. Pf by 28%. Ct. Ar and Ct. Th measured by u CT were also summarized in the Table 1. OVX did not affect the cortical area and thickness of tibial diaphysis. As shown in Table 2 and Figure 3, the histomorphometric parameters were analogous to the u CT observations of trabecular morphology: AG-1478 OVX significantly reduced BV/TV by 82%, Tb.

Th by 58%, Tb. N by 64%, and increased Tb. Sp by 604%. SM treatment ALK Inhibitor also tended to have a dose dependent preventive effect at the experimental dosages, but only treatment with the maximum of 30 mg/kg body weight/kg of SM showed significance, attenuating reduction of BV/TV by 19%, Tb. Th by 57%, and Tb. N by 65%, while preventing the increase of Tb. Sp by 69%. OVX also induced a significant increase in Oc. N, and SM treatment attenuated the Oc. N increase only in the 30SM group. As shown in Figure 4 and Table 3, OVX aggravated mononuclear cellular infiltration in the portal area of the liver and SM treatment significantly ameliorated mononuclear cellular infiltration only at 30 mg/kg body weight/day.

No comments:

Post a Comment